Aptus EndoStapling System receives CE Mark approval

Aptus Endosystems, Inc., a medical device company developing advanced technology for endovascular aneurysm repair (EVAR), announced CE Mark approval for the Aptus EndoStapling System. The innovative helical staple technology enables independent endograft fixation, and is designed to mimic the hand suturing performed during open surgical repair of abdominal aortic aneurysms. Aortic aneurysms are an enlarged and weakened section of the aorta which can be lethal if left untreated. Each year, an estimated 100,000 people in Europe and about 200,000 people in the U.S. are diagnosed with this condition. In EVAR, an alternative to open surgical repair, a metal and fabric endograft is implanted using a catheter-based delivery system to isolate blood flow away from the aneurysm to prevent potential rupture and death.

“We found the system to be a highly sophisticated, user friendly device, designed to be applied easily by the average user, requiring a short learning curve”

The EndoStapling System provides physicians with a novel technology to repair endovascular grafts that have exhibited migration or endoleaks (or are at risk of these complications which are commonly seen after EVAR) where augmented radial fixation and/or sealing is required to regain or maintain effective aortic aneurysm exclusion. The system also can be used during de novo EVAR procedures (at the time of initial endograft implantation) to enhance an endograft's inherent fixation and sealing mechanisms.

"The use of the Aptus EndoStapling system will be a great advantage to simplify revision surgery for migrated endografts," said Jean Paul de Vries, M.D., Ph.D., Head of the Department of Vascular Surgery, St. Antonius Hospital, Nieuwegein, The Netherlands. "The ability to staple migrated endografts to the aortic wall and to fixate extension cuffs will overcome most migrations and type IA endoleaks. This system truly mimics a sutured anastomosis."

In addition, de Vries said, "EndoStaples can improve fixation of de novo endografts in challenging proximal necks - short, large and angulated - and can potentially reduce distal migration during follow-up."

"We found the system to be a highly sophisticated, user friendly device, designed to be applied easily by the average user, requiring a short learning curve," said Theodossios Perdikides, M.D., Director of Vascular Surgery, Hellenic Air Force Hospital, Athens, Greece "I believe this innovative technology promises to prevent or repair major EVAR-related pitfalls that can lead to failure or even disaster."

"This is a big leap forward concerning minimally invasive bail-out for endografts at risk for migration," said Joerg Tessarek, M.D., Chief of Vascular Surgery, St. Bonifatius Hospital, Lingen, Germany. "Not only for traditional infrarenal devices, but also for complex fenestrated or branched grafts where migration affects target vessel patency, this will be a helpful tool to provide graft stability."

Aptus Endosystems CEO Jeff Elkins called the CE Mark approval a "significant milestone." He went on to comment that, "Given the recent publication of several long term EVAR outcome studies, we now recognize that late EVAR failure and the need for secondary intervention is a major underserved clinical need affecting many patients, and continued improvement in technology is required. To date, physicians have had limited prophylactic and treatment options for graft migration and Type I endoleaks. The novel concept of independent and physician controlled proximal fixation using the EndoStapling System is a considerable step toward addressing long term complications and making EVAR a more definitive solution for treating aortic aneurysms."

In addition to use with the Aptus endograft (which received CE Mark approval in 2009), the Aptus EndoStapling system has received CE approval for use with the Cook Zenith, Gore Excluder, and Medtronic AneuRx, Endurant, and Talent endografts in both initial implant and secondary repair settings. Use with other endografts has not been evaluated.


 Aptus Endosystems, Inc.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Medtronic. (2019, June 20). Aptus EndoStapling System receives CE Mark approval. News-Medical. Retrieved on May 22, 2022 from https://www.news-medical.net/news/20110524/Aptus-EndoStapling-System-receives-CE-Mark-approval.aspx.

  • MLA

    Medtronic. "Aptus EndoStapling System receives CE Mark approval". News-Medical. 22 May 2022. <https://www.news-medical.net/news/20110524/Aptus-EndoStapling-System-receives-CE-Mark-approval.aspx>.

  • Chicago

    Medtronic. "Aptus EndoStapling System receives CE Mark approval". News-Medical. https://www.news-medical.net/news/20110524/Aptus-EndoStapling-System-receives-CE-Mark-approval.aspx. (accessed May 22, 2022).

  • Harvard

    Medtronic. 2019. Aptus EndoStapling System receives CE Mark approval. News-Medical, viewed 22 May 2022, https://www.news-medical.net/news/20110524/Aptus-EndoStapling-System-receives-CE-Mark-approval.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Medtronic introduces new StealthStation S8 technology for neurosurgery